MariTide: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โขCommunity protocols detailed below
- โขEvidence level: Anecdotal Reports
- โขSee community reports below
- โขStacking patterns detailed below
Sources
- Reddit r/Peptides|MariTide and next-generation obesity drug discussions(accessed 2026-02-16)
- Reddit r/loseit|Monthly GLP-1 injection pipeline discussions including MariTide(accessed 2026-02-16)
- Amgen Press Release|Amgen Phase 2 MariTide results announcement(accessed 2026-02-16)
Community Evidence Overview#
This page documents the community evidence landscape for MariTide (maridebart cafraglutide, AMG 133). This is not clinical evidence and should not be used as medical guidance.
MariTide has no community self-experimenter data. It is an investigational antibody-peptide conjugate that can only be produced through complex biopharmaceutical manufacturing processes.
Why There Is No Community Data#
Complex Biologic Structure#
MariTide is an antibody-peptide conjugate consisting of an anti-GIPR monoclonal antibody conjugated to two GLP-1 analog peptides. At approximately 153 kDa, it is a complex biologic that cannot be synthesized by standard peptide manufacturers. It requires mammalian cell culture production and sophisticated conjugation chemistry.
Phase 3 Investigational Status#
MariTide is in Amgen's Phase 3 MARITIME clinical program. It is only available to patients enrolled in clinical trials and cannot be purchased through any commercial channel.
High Community Anticipation#
Despite the absence of self-experimenter data, MariTide generates significant community discussion in weight loss and obesity treatment forums:
- Monthly dosing appeal: The prospect of a single monthly injection versus weekly dosing is highly attractive to community members fatigued by frequent injections
- GIPR antagonism debate: Whether GIP receptor blocking (MariTide's approach) or GIP receptor agonism (tirzepatide's approach) produces better outcomes is a topic of active community debate
- Muscle preservation: Early data suggesting MariTide may preserve more lean mass during weight loss has generated particular interest
- Weight maintenance: The potential for extended dosing intervals appeals to those concerned about lifelong weekly injections
Pipeline Position#
MariTide competes in the monthly dosing space with zovaglutide (QL Biopharm) and MET-097i (Pfizer/Metsera). Community interest in less frequent dosing options continues to grow.
Related Reading#
- MariTide Research & Clinical Studies
- MariTide Molecular Profile
- Tirzepatide - Dual GLP-1/GIP agonist (agonist approach)
- Semaglutide - Weekly GLP-1 agonist
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About MariTide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.